What's Next for Beta Bionics, Inc. Shareholders After 37% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
Complaint alleges Beta Bionics, Inc. misled investors between July 30, 2025 and February 24, 2026; investors may seek lead plaintiff role by November 3, 2026
LOS ANGELES, Oct. 28, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class action lawsuit covers investors who bought Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) securities between July 30, 2025 and February 24, 2026. The Beta Bionics, Inc. case, Holtzman v. Beta Bionics, Inc., et al., was filed on September 4, 2026 in the U.S. District Court for the Central District of California (Case No. 8:26-cv-02612).
Investors who suffered losses on Beta Bionics, Inc. investments can submit their Beta Bionics, Inc. loss information here before the November 3, 2026 lead plaintiff deadline.
Key dates in the Beta Bionics, Inc. case
- Class period: July 30, 2025 to February 24, 2026
- Complaint filed: September 4, 2026
- Lead plaintiff deadline: November 3, 2026
What happened?
On January 8, 2026, Beta Bionics released preliminary fourth quarter 2025 financial results, revealing that new patient starts would be "up at least 36%" — lower than analysts had estimated for the quarter.
On this news, Beta Bionics' stock price fell $11.85, or 37%, to close at $20.15 per share on January 9, 2026, thereby injuring investors.
What is the Beta Bionics, Inc. lawsuit about?
The Beta Bionics, Inc. securities lawsuit alleges that, between July 30, 2025 and February 24, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Beta Bionics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Defendants omitted mention of the FDA Form 483 and iLet's underlying safety issues, including that the Form 483 identified over 18,000 complaints including numerous life-threatening hypoglycemic events that the Company had "failed to investigate," or even report to the FDA, with no justification; (2) the Company's statements assuring investors that its remediation efforts were advanced and the FDA's issues were "very benign," failed to accurately describe the scope and severity of the FDA's observations which made remediation much more complex and extensive than Defendants indicated to investors; (3) that the Company "could have opened a CAPA and did not" was misleading where the FDA had in fact concluded that Beta Bionics had, without justification, failed to investigate clearly serious, life-threatening customer reports; and (4) as a result, defendants' positive statements about Beta Bionics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
"The complaint against Beta Bionics, Inc. alleges, among other things, that the Company failed to disclose that Defendants omitted mention of the FDA Form 483 and iLet's underlying safety issues, including that the Form 483 identified over 18,000 complaints including numerous life-threatening hypoglycemic events that the Company had "failed to investigate," or even report to the FDA, with no justification. For investors who purchased during the class period, the November 3, 2026 lead plaintiff deadline is the first significant deadline to keep in mind," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.
What's the next step?
Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist Beta Bionics, Inc. investors in potentially pursuing claims to recover their losses.
If you wish to serve as lead plaintiff in the Beta Bionics, Inc. class action, you must move the Court no later than November 3, 2026. To learn more about your rights, visit the Beta Bionics, Inc. case page, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224).
You may retain counsel of your choice. If you bought Beta Bionics, Inc. securities during the class period, you may take no action and remain an absent class member. No class has been certified yet in the Beta Bionics, Inc. case.
Frequently Asked Questions
Who is eligible? Investors who purchased or otherwise acquired Beta Bionics, Inc. securities between July 30, 2025 and February 24, 2026 and suffered losses may be members of the proposed class in the Beta Bionics, Inc. shareholder lawsuit. Any class member may ask the court to appoint them lead plaintiff by November 3, 2026.
What is a lead plaintiff? In the Beta Bionics, Inc. class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff.
Do I have to be lead plaintiff to recover? No. A Beta Bionics, Inc. investor's ability to share in any future recovery does not depend on serving as lead plaintiff. Beta Bionics, Inc. investors may take no action and remain absent class members.
What is the deadline? Motions to serve as lead plaintiff in the Beta Bionics, Inc. class action must be filed by November 3, 2026.
Does it cost anything to contact Glancy or participate in this action? Glancy represents Beta Bionics, Inc. investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.
Can I choose my own lawyer? Yes. Beta Bionics, Inc. investors may retain counsel of their choice.
Why work with Glancy on the Beta Bionics, Inc. lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Beta Bionics, Inc. lawsuit. Prior results do not guarantee a similar outcome.
About Glancy Prongay Wolke & Rotter LLP
Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.
Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
Prior results do not guarantee a similar outcome.
Related links
- Beta Bionics, Inc. case page, Glancy Prongay Wolke & Rotter LLP
- Complaint: Holtzman v. Beta Bionics, Inc., et al., U.S. District Court for the Central District of California
- press release
- Beta Bionics, Inc. SEC filings index, EDGAR
- Glancy Prongay Wolke & Rotter LLP
Contact
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Email: [email protected]
Telephone: 310-201-9150 | Toll-free: 888-773-9224
Follow Glancy on LinkedIn, X, or Facebook.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Glancy Prongay Wolke & Rotter LLP
Share this article